First Participant Dosed in Tisento Therapeutics’ Global Phase 2b PRIZM Study Evaluating Zagociguat for the Treatment of MELAS
January 27, 2025 07:00 ET
|
Tisento Therapeutics Inc
The first patient has been dosed in Tisento's global Phase 2b PRIZM study investigating zagociguat in MELAS.
UMDF and Khondrion Announce The Mito Fund’s Investment in Khondrion to Support Development of One of the Most Advanced Drug Candidates for Primary Mitochondrial Disease
November 21, 2024 07:00 ET
|
Khondrion
21 November 2024 – The United Mitochondrial Disease Foundation’s (UMDF) venture philanthropy arm, The Mito Fund, has invested in Khondrion, a Netherlands-based clinical stage biopharmaceutical company...
OMEICOS Therapeutics Completes Enrollment of PMD-OPTION Study in Primary Mitochondrial Disease
September 26, 2024 06:00 ET
|
OMEICOS Therapeutics GmbH
Interim data confirms OMT-28’s strong safety profile in PMD patients, top-line data expected mid-2025 BERLIN, GERMANY, September 26, 2024 – OMEICOS, a biopharmaceutical company developing...
Khondrion appoints Jasper Levink as Chief Financial and Business Officer
September 11, 2024 07:00 ET
|
Khondrion
Khondrion appoints Jasper Levink as Chief Financial and Business Officer NIJMEGEN, the Netherlands – 11 September 2024: Khondrion, a clinical stage biopharmaceutical company discovering and...
Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company
November 22, 2022 07:00 ET
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that the Board of Directors of the Company acting solely by all of its independent and...
Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy
October 06, 2022 08:00 ET
|
Cyclerion Therapeutics, Inc.
Recent positive MELAS clinical study data drive urgency to deliver potential first-ever therapy for patients with rare, genetic mitochondrial diseases Development programs prioritized and...
Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results
August 09, 2022 16:00 ET
|
Cyclerion Therapeutics, Inc.
Positive topline results for CY6463 announced in two clinical studies in patients with Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Cognitive Impairment...
Cyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation
June 28, 2022 09:00 ET
|
Cyclerion Therapeutics, Inc.
Data for CY6463, a first-in-class, CNS-penetrant, sGC stimulator, demonstrate safety and positive effects across biomarkers of disease in MELAS patients Company leadership discussed key insights for...
Cyclerion Therapeutics to Discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation
June 22, 2022 08:30 ET
|
Cyclerion Therapeutics, Inc.
Company to discuss positive topline and additional clinical data for CY6463 in MELAS patients Mitochondrial disease clinician-researcher, Amel Karaa, M.D., to discuss the potential future impact on...
Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease
June 17, 2022 08:00 ET
|
Cyclerion Therapeutics, Inc.
CY6463 alleviated mitochondrial dysfunction and reduced inflammation in preclinical models of mitochondrial complex 1 deficiency Data provide support for ongoing CY6463 clinical studies in CNS...